SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (349)8/7/1998 11:05:00 PM
From: Cacaito  Read Replies (1) | Respond to of 1494
 
Neurogen announced patents on CRF genomics, is this the same CRF that NTII names Xerepcet? It seems that both refers to the corticotropin releasing factor. Implications for NTII anybody?



To: Dr. John M. de Castro who wrote (349)11/7/1998 6:25:00 PM
From: BRAVEHEART  Read Replies (2) | Respond to of 1494
 
Hi John,

I was just going over prior posts. Could you shed any more light on the following post.

Here is another indication of the potential for Memantine. Memantine can prevent this apoptosis by a noncompetitive block of the NMDA receptor.

This is a link to the news story.

infobeat.com

This is the link to the original report.

ncbi.nlm.nih.gov.

Thanks
Jeffrey


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News